Study of HPV Vaccine adverse events and protection in patients with Juvenile Lupus and Juvenile Dermatomyositis

Phase 2

• Conditions: M32.8; M33.0; Juvenile Systemic Lupus Erythematosus; Juvenile Dermatomyositis

• Registration Number: RBR-9ypbtf
• Lead Sponsor: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-12-02
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Being female; Be between 9-20 years old; Have been diagnosed with one of the following immune system disorders before the age of 17 and before their first quadrivalent vaccine against human papillomavirus: juvenile systemic lupus erythematosus or juvenile dermatomyositis; Have not received the three doses of the quadrivalent human papillomavirus vaccine

Exclusion Criteria

The absence of parental consent for those under 18 or consent from the patient or control; refusal of any blood collection; hx of suspected or proven cervical carcinoma; being pregnant

Study & Design

• Study Type: Intervention
• Study Design: Not specified